FDA approval

Alpha Cognition’s ZUNVEYL Receives FDA Approval to Treat Alzheimer’s Disease

by | Jul 29, 2024
“The approval of ZUNVEYL is a pivotal moment in the fight against Alzheimer's disease as it's only the second oral AD treatment to be approved in more than a decade," said CEO Michael McFadden of Alpha Cognition. Based in Vancouver with an office in Frisco, the company was honored at the 2023 BioNTX iC3 Summit as one of eight "Rising Stars."
MORE
Reata CEO Warren Huff
Plano’s Reata Pharmaceuticals Launches First Product: The Rare-Disease Drug Skylarys
by | Jun 29, 2023
Reata cleared the final FDA hurdle to get its rare-disease drug Skylarys on the market, the company announced Tuesday. The drug is now available to U.S. patients who've been diagnosed with Friedreich’s ataxia—a genetic disorder that can cause progressive damage to the nervous system. The announcement marks Reata’s first drug approval since the company was founded in 2002, according to the Dallas Morning News.
MORE